Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) (Businesswire) - Sep 6, 2023 - "Endeavor BioMedicines...announced that the company has completed enrollment in its Phase 2a clinical trial to evaluate the safety and efficacy of ENV-101 (taladegib) for the treatment of idiopathic pulmonary fibrosis (IPF). ENV-101 is a small-molecule inhibitor of the Hedgehog (Hh) signaling pathway, which plays a critical role in IPF disease pathology....'This enrollment milestone is an important achievement, and we look forward to reporting topline results in Q1 of 2024.'"
Enrollment closed • P2a data • Idiopathic Pulmonary Fibrosis • Immunology
|